Equities research analysts expect Humana Inc. (NYSE:HUM) to report sales of $13.31 billion for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Humana’s earnings. The lowest sales estimate is $13.11 billion and the highest is $13.55 billion. Humana posted sales of $13.69 billion during the same quarter last year, which suggests a negative year over year growth rate of 2.8%. The company is expected to issue its next quarterly earnings report on Friday, November 3rd.

On average, analysts expect that Humana will report full-year sales of $13.31 billion for the current year, with estimates ranging from $52.60 billion to $54.29 billion. For the next financial year, analysts anticipate that the firm will post sales of $56.53 billion per share, with estimates ranging from $54.59 billion to $58.34 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Humana.

Humana (NYSE:HUM) last released its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same quarter in the previous year, the business earned $2.30 earnings per share.

A number of analysts have weighed in on HUM shares. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Monday, April 24th. Cowen and Company restated a “buy” rating and set a $230.00 target price on shares of Humana in a research report on Friday, July 14th. Cantor Fitzgerald restated a “neutral” rating and set a $223.00 target price (up from $200.00) on shares of Humana in a research report on Thursday. Jefferies Group LLC restated a “hold” rating and set a $257.00 target price on shares of Humana in a research report on Friday. Finally, Piper Jaffray Companies restated a “buy” rating and set a $246.00 target price on shares of Humana in a research report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. Humana currently has a consensus rating of “Hold” and a consensus target price of $243.00.

In other news, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at $3,421,920. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Heidi S. Margulis sold 1,500 shares of the business’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the transaction, the vice president now directly owns 8,150 shares of the company’s stock, valued at $1,890,474. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by company insiders.

Several institutional investors have recently made changes to their positions in the company. Guardian Life Insurance Co. of America boosted its stake in Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the last quarter. Independent Portfolio Consultants Inc. boosted its stake in shares of Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after buying an additional 94 shares in the last quarter. Point72 Asia Hong Kong Ltd purchased a new stake in shares of Humana during the first quarter worth $128,000. Westbourne Investment Advisors Inc. purchased a new stake in shares of Humana during the second quarter worth $205,000. Finally, Hengehold Capital Management LLC purchased a new stake in shares of Humana during the second quarter worth $209,000. 99.66% of the stock is owned by institutional investors and hedge funds.

Humana (NYSE:HUM) traded up 1.50% during midday trading on Friday, reaching $249.62. 1,068,145 shares of the company’s stock traded hands. The company’s 50-day moving average price is $236.19 and its 200-day moving average price is $220.68. The stock has a market cap of $36.07 billion, a P/E ratio of 20.53 and a beta of 0.91. Humana has a 52-week low of $163.50 and a 52-week high of $251.79.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/07/humana-inc-nysehum-expected-to-post-quarterly-sales-of-13-31-billion.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.